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ABSTRACT 
 
 
BACKGROUND 
 
Several studies have indicated that subjects with periodontal disease may have 
a higher risk for cardiovascular disease when compared to subjects with a healthy 
periodontium (Mattila et al 1989, Beck et al 1998, Loesche 1998). 
Also, Periodontitis & Cardiovascular disease may share common risk factors such as 
Smoking, Diabetes, Ageing, and Male genders. 
 
AIM 
 
To measure the level of fasting plasma lipid profile and blood glucose levels 
in chronic periodontitis patients and compare and correlate the results with those 
obtained in age and sex matched healthy individuals. 
 
MATERIALS AND METHODS 
 
30 subjects with chronic periodontitis divided into mild, moderate and severe 
study group based on CAL and 30 age and sex matched healthy controls participated 
in this study. Venous blood sample was collected by experienced trained person in the 
morning after an overnight fast and analyzed for serum triglycerides, total cholesterol 
LDL, HDL and blood glucose in the study and control group. Periodontal parameters, 
namely, probing pocket depth and CAL were recorded on full mouth basis at 6 sites 
per tooth. All measurements were made using William’s periodontal probe in both 
study and control group. 
 
RESULT 
 
Triglycerides were significantly higher in periodontally diseased subjects 
(P<0.000) when compared with controls. When the mild, moderate and severe 
periodontitis patients  in the study group were clumped as one group and compared 
with controls, statistically significant values were obtained for Total Cholesterol 
(P<0.002)and Triglycerides (P<0.000). Also, we found significantly higher values in 
blood glucose levels in patients than in the control group. 
 
CONCLUSION 
 
It is likely that severity and poor control of periodontal disease might affect 
the level of lipids and glucose in blood which may increase the risk for CVD. 
Therefore, when periodontitis is newly diagnosed in patients with atherosclerotic 
CVD, periodontists and physicians managing patients with CVD should closely 
collaborate to optimize CVD risk reduction & periodontal care 
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INTRODUCTION 
 
Periodontal diseases are among the most prevalent and widely spread diseases 
worldwide contributing mainly to tooth morbidity and mortality. It is the chronic 
immuno-inflammatory response to the bacteria and their products may result in 
periodontal destruction. 
Periodontal disease may be more frequent and severe in individual with long 
duration of the disease and those with systemic complication. On the other hand, it 
may also occur in patients with well controlled systemic conditions. There is 
increasing evidence that periodontal infections may play a role in systemic disease not 
only in ill and immuno compromised individuals, but also in healthy individuals. 
Infection produces changes in the lipid metabolism that may favor 
atherosclerosis. The initiation of atherosclerosis is due to focal accumulation of lipids. 
Periodontitis and Atherosclerosis have complex etiologies, genetic and gender 
predispositions and potentially share many risk factors.  
Diabetes mellitus, caused by the malfunction of insulin-dependent glucose and 
lipid metabolism, presents with the classical triad of symptoms: polydypsia, polyuria, 
and polyphagia which are often accompanied by chronic fatigue and loss of weight. 
Complications of diabetes mellitus include retinopathy, nephropathy, neuropathy, and 
cardiovascular disease.. Periodontitis being considered as the sixth complication of 
diabetes.  
 Periodontitis is caused by a small group of gram negative bacteria present on 
the root surfaces as biofilms. Lipopolysaccharide (LPS) and other microbial 
substances gain access to the gingival tissues, initiate and perpetuate 
immunoinflammation, resulting in the production of high levels of proinflammatory 
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cytokines. These induce production of matrix metalloproteinases which destroy the 
connective tissues of the gingiva, cementum and periodontal ligament, and 
prostaglandins which mediate alveolar bone destruction. Periodontitis may enhance 
susceptibility to systemic diseases in several ways. LPS and proinflammatory 
cytokines from inflamed periodontal tissue may enter the circulation in pathogenic 
quantities. This will result in increase in serum lipid levels and state of insulin 
resistance. Many studies suggest that chronic low level systemic exposure to LPS 
leads to generalized alteration in lipid and glucose metabolism. Thus periodontitis 
induced insulin resistance & hyperlipidemia if longstanding or chronic are considered 
to be precursors to active diabetes and cardiovascular diseases due to sustained 
elevations of proinflammatory cytokines. 
In addition, Periodontitis and certain systemic diseases, such as cardiovascular 
disease share common risk factors including smoking, male gender, race/ethnicity, 
stress, genetic and aging. There is an abundance of evidence that chronic 
periodontitis, especially severe periodontitis in early life, significantly enhances risk 
for systemic disease. The purpose of this study is to demonstrate how untreated 
periodontitis influence the general health by altering the lipid and glucose 
metabolism. 
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AIM AND OBJECTIVES 
 
The aim of the present study was to determine whether there is an alteration in 
the levels of blood glucose and lipid profile in patients with Chronic Periodontitis, 
when compared to individuals with healthy periodontium. 
 
For this purpose, the following objectives were undertaken: 
1. To compare the fasting blood glucose and lipid profile levels in individuals 
with healthy periodontium (Control Group) and Chronic Periodontitis (Study 
Group). 
2. To correlate the levels of blood glucose and lipid profile of the Study Group 
with the clinical parameter of Clinical Attachment Loss within the same 
group. 
3. Whether the alteration in the blood biochemical parameter increases with 
increase in the severity of the disease? 
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REVIEW OF LITERATURE 
 
HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE  
For more than half century, observational epidemiological studies have 
investigated whether elevated plasma lipids has any association with an increased risk 
of coronary heart disease. 
 Oral sepsis was first introduced into the medical literature in a report entitled 
Oral sepsis as a cause of systemic disease by William Hunter in 190099. This was 
then superseded by focal infection, introduced by Frank Billings in 19219. 
 Focal infection has been continued to be explored as a possible cause or 
exacerbating factor of some systemic conditions, but presently it is being evaluated on 
scientific basis. The concept of focal infection, while shifting in and out of favor as a 
pathogenic mechanism has always been recognized as being potentially causal in 
bacterial endocarditis due to bacteremia.  
 Albink et al3 was the first to report an association between triglyceride and 
myocardial infarction (MI) in a case-control study published in 1959. Since that time, 
many  case control or cross-sectional design have been reported with an increased risk 
of coronary heart disease (CHD).In many of the studies, the association of triglyceride 
and outcome was analyzed, after controlling for either total plasma cholesterol (TC) 
or low density lipoprotein cholesterol (LDL-C). In each study, the association of 
triglyceride with CHD persisted after taking into account TC or LDL-C level. Some 
of the studies in which possible confounding effects of high density lipoprotein 
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cholesterol (HDL-C) were also considered, the triglyceride association remained 
significant. 
 Elevated concentrations of serum cholesterol and triglycerides have both been 
implicated in the pathogenesis of Coronary Artery Disease (CAD). (Albrink et al 
19593 , Brown et al 196511 , Keys et al 197552). Crowley and his Associates in 
197122 confirmed serum lipid concentration in patients with CAD by coronary 
arteriograph. In the presence of hypercholesterolemia, the platelets become 
hyperactive which will increase the tendency toward platelet thrombus formation 
(Carvalho et al 197418, Stuart et al 198091, Davi et al 199226). A report by Cohn et 
al in 197619 stated that CAD has continuous relationship with concentration of serum 
cholesterol and to lesser extent serum triglycerides. 
 Keys et al in 198053 confirmed that hypercholesterolemia as a risk factor for 
IHD and coronary artery disease mortality. Risk of MI was directly related to 
concentration of cholesterol and LDL- C and inversely related to HDL-C (Gordon  
198144) 
 Although studies of lipids and the degree of coronary atherosclerosis began in 
the late 1960s, uncertainty remained up to now over which lipid measurement 
discriminates the degree of CAD. Discussions over which is the "most influential" 
lipid parameter have been particularly unrewarding .Both TC and HDL cholesterol, 
when considered together, remained strongly related to the presence and extent of 
CAD. This denotes the importance of TC and HDL cholesterol as predictors of CAD. 
 Lowering blood cholesterol levels reduces coronary events in subjects both 
without (Frick et al 198736, Law et al 199457) and with (Rossouw et al 199082, 
Buchwald et al 199014, Brown et al 199013) known coronary disease. Secondary 
intervention studies have demonstrated that decreasing LDL cholesterol and 
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increasing HDL-C in dyslipidemic patients with angiographically assessed CAD are 
accompanied by less progression and more regression of atherosclerotic 
lesions.(Blankerhorn et al 199310). Improved endothelial function (Drexler et al 
199128) and inadequate plaque stabilization due to a decrease in the lipid content of 
the lesions most likely to rupture (Brown et al 199312). These are two mechanisms 
that could partly account for the reduction in coronary events with cholesterol 
lowering. Another mechanism is a decrease in the tendency toward platelet thrombus 
formation with cholesterol lowering. 
 Ignasi Bolibar48 and his associates on behalf of the Angina Pectoris Study 
Group in 1995 emphasized the role of serum lipid levels in determining not only the 
presence but also the extent of atherosclerotic disease in coronary arteries. 
 
DIABETES AND CVD: 
 There are numerous plausible biological mechanisms to explain the early 
development of atherosclerosis and poor outcome of patients with diabetes and CVD. 
Patients with Type 2 diabetes develop abnormal endothelial function, platelet 
hyperactivity, aggressive atherosclerosis, a propensity for adverse arterial remodeling, 
enhanced cellular and matrix proliferation following arterial injury, and impaired 
fibrinolysis with a tendency for thrombosis and inflammation. 
 In an early case control study of 101 diabetic subjects, triglyceride was 
significantly associated with atherosclerosis in both men and women (Santen et al 
197287). It is well established that risk for CHD is increased in diabetics and that risk 
factors levels are also elevated.(Garcia et al 197440, Jarrett et al 198247) 
 Four large prospective studies have shown that hyperinsulinemia is a predictor 
of coronary artery disease (CAD), with a few prospective reports not demonstrating 
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such a relationship. The greatest association of hyperinsulinemia with CAD has been 
found in Finland in a population with a very high frequency of CAD .Insulin 
resistance has been hypothesized to play a major role in dyslipidemia in individuals 
with normal glucose tolerance, as well as in those with impaired glucose tolerance and 
type 2 diabetes .(Garg 198841)  
Impaired endothelial function is not only antecedent to the development of 
atherosclerosis but also is demonstrable in the early stages of diabetes (Mc.Veigh et 
al 199267). Several studies have shown a relationship between carotid wall 
atherosclerotic lesions, angina, and insulin levels/resistance (Saloma et al 199585). 
Results of a prospective investigation of 2103 men from Quebec clearly showed that 
high fasting insulin concentrations are an independent predictor of CAD (Desperes  et 
al 199627). This important study used an insulin assay without cross-reactivity with 
proinsulin, thus avoiding that confounding influence.  
` Abundant evidence shows that patients with type 1 diabetes or type 2 diabetes 
are at high risk for several cardiovascular disorders: coronary heart disease, stroke, 
peripheral arterial disease, cardiomyopathy, and congestive heart failure. 
Cardiovascular complications are now the leading causes of diabetes-related 
morbidity and mortality. 
Prospective studies, such as the Framingham40, Honolulu, and San Antonio 
Heart Studies, as well as numerous more recent population studies in the United 
States and other countries, have documented the excess CVD risk in patients with 
diabetes from multiple racial and ethnic groups 
 The American Diabetes Association and the Juvenile Diabetes Foundation 
International have long emphasized the importance of identifying and applying 
interventions that help patients with diabetes reduce their risk for CVD. In addition, 
 8
the growing importance of diabetes as a cause of CVD has led the American Heart 
Association (AHA) to formally designate diabetes as a major risk factor for CVD. 
This will place diabetes on a coequal status with cigarette smoking, hypertension, and 
cholesterol disorders as major CVD risk factors. 
Recent controlled trials of cholesterol-lowering therapy, particularly secondary 
prevention trials, showed that reducing low density lipoprotein cholesterol levels 
results in a striking decrease in major coronary events in patients with type 2 diabetes. 
The Diabetes Control and Complication Trial (DCCT46) showed that the improved 
glycemic control can prevent or reduce microvascular disease and may reduce 
macrovascular disease in patients with type 1 diabetes. 
The United Kingdom Prospective Diabetes Study (UKPDS46) demonstrated 
similar benefits in decreasing microvascular disease by controlling hyperglycemia in 
patients with type 2 diabetes and also reported that glycemic control probably reduces 
macrovascular disease. Recent studies suggest that the absolute risk for major 
coronary events in patients with type 2 diabetes approaches that of nondiabetic 
patients with established coronary heart disease. Worse, once patients with diabetes 
develop clinical coronary heart disease, they have a particularly bad prognosis, both 
acutely in the postinfarction period and over the long term. 
It is important to recognize that the pathogenesis of diabetes-associated CVD 
is only partially understood and that expanded basic and clinical research is needed to 
determine the best and most efficacious ways to reduce cardiovascular complications 
in these high-risk patients. (Grundy SM 199946) 
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INFLAMMATION AND CVD: 
 Epidemiological and clinical studies have shown strong and consistent 
relationships between markers of inflammation and risk of future cardiovascular 
events. Inflammation occurs in the vasculature as a response to injury, lipid 
peroxidation, and perhaps infection. 
Early in the process, in response to oxidized low-density–lipoprotein 
cholesterol (LDL-C), injury or infection, resident or circulating leukocytes bind 
monocytes to the site of a developing lesion. As they continue to ingest chemically 
modified lipids and lipoproteins, monocytes become macrophages, or foam cells, and 
initiate fatty streaks. In 1994, Moreno et al72 stated that more than half of all cells at 
the immediate site of plaque rupture are macrophages; they are the dominant type of 
atherosclerotic inflammatory cell infiltrates. At the same time, other inflammatory 
mediators, including activated T cells and mast cells, also attach themselves to the 
endothelium. All of these inflammatory cells eventually contribute to the formation of 
the atheromatous lesion which consists of a lipid pool protected by a fibrous cap. The 
monocyte-macrophages release metalloproteinases. These proteolytic enzymes can 
break down collagen in the fibrous cap, leaving it prone to rupture, and exposing the 
tissue factor and atherosclerotic debris beneath to arterial blood, inducing thrombosis. 
Fuster et al in 199437 demonstrated that risk of plaque rupture correlates 
poorly with the degree of stenosis: half of all infarctions occur in arteries that have 
_50% luminal diameter narrowing. Falk et al 199531 evaluated the risk of plaque 
rupture exists with a thin fibrous cap, and inflammatory cells within and under the cap 
In a quarter of cases, plaque does not rupture; the endothelium is simply replaced by 
the prothrombotic inflammatory cells. These cells also release procoagulant tissue 
factor, which contributes to thrombogenesis .Smooth muscle cells (SMCs) secrete 
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factors that recruit additional monocytes. Local stimulation of SMCs in the artery wall 
can amplify the inflammatory response and promote a local procoagulant effect. 
(Libby et al 200158). 
The final steps in the inflammatory cascade occur when plaque contents—
cholesterol, macrophages, tissue factor, necrotic debris, and platelet derived 
prothrombotic substances (thromboxane A2, serotonin, adenosine diphosphate, 
platelet-activating factor)— come into contact with the blood and thrombosis ensues. 
The results may be either coronary or cerebral infarction, depending on the duration 
of the thrombosis and the location of the associated vasoconstriction. (Willerson 
200298). 
 Thus inflammation plays a role in all stages of atherothrombosis, the 
underlying cause of approximately 80% of all sudden cardiac death (Albert et al 
20022) 
 
INFECTION AND INFLAMMATION INDUCE LDL OXIDATION 
IN VIVO 
Some studies have suggested that specific infectious agents play a direct role 
in the vessel wall in the formation of atherosclerotic lesion,both infection and 
inflammation are accompanied by a systemic host response known as the acute-phase 
response (APR)(Mendall MA, 199569).  
Plasma ceruloplasmin levels are increased during Acute phase response, and 
purified ceruloplasmin has been shown to increase oxidation of LDL in cell-free 
systems as well as in cultured endothelial, smooth muscle (Gitlin 1988 42 ) 
Research has recently shown that human atherosclerotic plaques contain massive 
amounts of lipid peroxidation products, despite the presence of large quantities of a-
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tocopherol and ascorbate. (Suarna C, 199592).APR is accompanied by alterations in 
lipid metabolism that include increased serum triglycerides and decreased HDL 
levels. (Gabay  199938) 
Transferrin is another metal-binding protein associated with HDL. Hepatic 
synthesis and serum levels of transferrin are decreased during APR. APR may lead to 
less transferrin in HDL, which makes it less effective for protection of LDL against 
oxidation. ( Kunitake et al 199256) 
The LPS-induced increase in serum triglycerides occurs within 90 minutes, 
whereas changes in oxidized lipids are not seen until 24 hours after LPS treatment, 
which indicates that increase in oxidized lipids in serum is not simply a result of 
increased availability of fatty acid substrate. These results indicate that the host 
response to infection and inflammation is a potent stimulus for producing oxidation of 
serum lipids, including circulating LDL. (Feingold et al 199234) 
Several structurally unrelated antioxidants slow the progression of 
atherosclerosis; whereas oxidized lipids in the diet enhance atherosclerosis (Staprans 
et al 199690.).Oxidative modification of lipoproteins plays a central role in the 
pathogenesis of atherosclerosis. Lipoproteins with oxidative damage and lipid 
peroxidation products have been detected in atherosclerotic lesions (Berliner et al 
19968) 
Circulating LDL is protected from oxidative stress by HDL associated 
enzymes, particularly paraoxonase, which destroys biologically active oxidized 
phospholipids (Mackness et al 199662 ). 
 Van Lenten et al95 have shown that serum paraoxonase activity is decreased 
in rabbits after croton oil administration and paraoxonase depleted HDL is unable to 
protect LDL from oxidation in vitro. Feingold et al33 reported that LPS, Tumor 
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necrosis factor, and Interleukin-1 decrease serum paraoxonase activity and hepatic 
paraoxonase mRNA levels in Syrian hamsters in vivo which suggests that the 
decrease in paraoxonase is a feature of APR. 
Increased LDL oxidation that occurs during infection and inflammation could 
be one of the mechanisms that promote atherosclerosis in patients with chronic 
infections and inflammatory diseases. 
 
PERIODONTAL DISEASE AND CVD: 
Korn et al in 196255 stated that transient bacteremia occurs with manipulation 
of periodontal tissues .Gingivectomy and root planning are reported to cause 
bacteremia in 55 to 80% of cases. 
In the late 1970s, experimental infection of germ-free chickens with an avian 
herpesvirus induced an arterial disease that resembled human atherosclerosis (Minick 
et al., 197970 ). This finding initiated the ‘systemic infection-heart disease’ paradigm 
The invasiveness of procedures as a cause of distant site infection is therefore 
unclear and little is known about the relative incidence, nature magnitude and 
duration of bacteremia from a wide variety of dental procedures. 
(Guntheroth,198447 ).    
  Clinicians have noted that periodontitis patients & ischemic heart disease 
patients have a number of characteristics in common. Studies have reported that heart 
disease is the condition most commonly found in periodontitis patients.(Nevy et al 
198774 ). Mattila and colleagues were the first to show a statistical association 
between dental infections and advanced coronary atherosclerosis (Mattila et al., 
1989b66 ).According to the study by Syrjänen and co-workers, dental infection was 
associated with cerebral infarction in young and middle-aged men (Syrjänen et al., 
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198993 ) and the study by Paunio et al. (199379)  reported that missing teeth were 
associated with ischemic heart disease. 
Destructive periodontal disease which involves Gram-negative bacteria, has 
been reported to be a significant predictor of coronary heart disease (Beck et al., 
19967). Because both coronary heart disease (CHD) and periodontal disease have a 
multi-factorial etiology, as well as a wide variety of possible confounding factors, a 
clear-cut consensus on the importance of the relationship between these two 
conditions has been difficult to obtain 
Loesche et al.(199860)  published a study in which the confounding variables 
were well-controlled, and the results seemed to suggest a positive association between 
dental disease and cerebrovascular accidents in US veterans. However, this study was 
cross-sectional and causal inferences could not be made. 
Since cardiovascular diseases are the leading cause of death worldwide, 
greater attention has been focused on evidence that infections of the oral cavity might 
be associated with atherothrombosis: heart infarction, stroke, and peripheral vascular 
disease (Slavkin and Baum, 200089). 
 In Sweden, Buhlin and co-workers have published a national questionnaire 
study in which a significant association was observed between self-reported bleeding 
gums and CVD  and between the presence of dentures and CVD. The data analysis 
was adjusted for age, smoking, income level, socio-economic and marital status, and 
education (Buhlin et al.,200215).The same group also reported results from another 
questionnaire which suggested that the risk of CVD was increased if the patient had 
experienced problems with his/her teeth in the absence of dental care. Here, the odds 
ratio for the association of self-reported bleeding gums and CVD was 3.07 (CI 1.288–
7.313) (Buhlin et al., 2003a16).  
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 In the last ten years, several epidemiological studies have assessed the 
association between oral infection and systemic disease (Renvert, 200380). These 
studies have provided support that oral infections, specifically periodontitis, may 
confer independent risks for different systemic conditions (mortality, osteoporosis, 
diabetes mellitus, pulmonary infections, pre-term low-weight births, cardiovascular 
diseases, and infections in other body sites). 
Nevertheless, we agree with Mattila (200365), the original presenter of the 
hypothesis linking dental infection and CVD, that the measurement of alveolar bone 
loss as recommended by Rutger Persson et al.(200383) might be the best way to 
assess the severity of periodontal disease in large studies, because the radiographic 
assessment can be done in a blinded fashion, and several independent researchers can 
be used. 
Richard Castillo in 200981 studied the relationship between atherosclerosis 
and tooth loss and found that atherosclerosis and dental loss are age dependent and are 
interrelated independent of age. 
PATHOPHYSIOLOGY 
Studies in humans/baboons have shown a number of cytokines are produced in 
response to systemic Gram-negative LPS exposure. Two principal cytokines involved 
in this response are TNF-alpha and IL- 1beta. Their appearance in the plasma has a 
well-defined temporal relationship indicative of a “cytokine cascade.” TNF- alpha is 
the first factor in this cascade followed by IL-1 beta. It is believed that these cytokines 
exert effects on lipid metabolism by influencing production of other cytokines, 
altering hemodynamics/amino acid utilization of various tissues involved in lipid 
metabolism, or modifying the hypothalamic-pituitary-adrenal axis increasing plasma 
concentrations of adrenocorticotropic hormone, cortisol, adrenaline, noradrenaline, 
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and glucagon. Thus, through action of TNF- alpha and IL-1 beta, exposure to 
microorganisms/endotoxin results in elevated levels of free fatty acids (FFA), LDL, 
and TRG. These elevations in serum lipids are thought to arise from enhanced hepatic 
lipogenesis, increased adipose tissue lipolysis/blood flow, increased synthesis or 
reduced clearance of TRG, and reduced clearance of LDL due to reductions in 
lipoprotein lipase activity. Thus, any condition producing elevations in serum IL-1 
beta /TNF- alpha has potential to cause hyperlipidemia. In the case of periodontitis, 
elevations of these cytokines may be mediated by “systemic dumping” of locally 
produced IL-1beta/TNF-alpha and/or low-level “asymptomatic 
bacteremia/endotoxemia.” .This would be especially problematic in diabetic patients 
who may already exhibit elevated serum lipids and a systemic monocytic hyper-
response trait. 
 
PERIODONTITIS AND HYPERLIPIDEMIA: 
Animal studies have demonstrated a causal relationship between 
hyperlipidemia and periodontitis. Investigations in rats by Ueno et al in 196594 have 
demonstrated that animals placed on high fat diet develop periodontitis. 
 The study of Feingold et al 199234 showed that the administration of low 
doses of endotoxins in rats resulted in hypertriglyceridemia suggesting the presence of 
a similar response in local infections such as periodontal disease. 
 The study of Memon et al 199368 has proved that induction of periodontitis by 
P.gingivalis in rats resulted in increased level of TGL. Using similar methodology, the 
same result was observed in work of Doxey et al in 199829. 
 Studies in non human primates by Ebersole et al in 199930 have demonstrated 
elevations in serum lipids of inflammatory biomarkers and LDL/TRG during 
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gingivitis and periodontitis. Additionally these changes were exacerbated by high fat 
diet and animals on high fat diet exhibited more severe periodontitis.  
 Human studies appear to confirm the hyperlipidemia periodontitis 
relationship. Subjects with hyperlipidemia demonstrated significantly more severe 
periodontitis than community based controls and the degree of periodontal breakdown 
was positively correlated to plasma lipid levels (Pohl et al 199578). A study 
measuring serum lipid levels in systemically healthy patients with moderate 
periodontitis by Netea et al in 199773 showed a significant elevation of serum 
LDL/TRG in periodontitis patients compared to controls. 
 Studies involving clinical evaluation/ laboratory assessment of healthy and 
diabetic patients suggest a potential linkage between periodontitis, elevated serum 
lipid and level of bacteremia(Cutler et al 199923) . Analysis of sera from random 
healthy clinic patients demonstrated significant elevations of serum lipids and 
P.gingivalis titers in patients with periodontitis compared to patients without 
periodontitis. It is also demonstrated significant association of the presence of disease 
with total serum cholesterol, TRG and amount of P.gingivalis antibodies (Cutler et al 
199924). 
 According to National Cholesterol Education Program periodontal disease was 
more prevalent in subjects with a serum HDL-C concentration <60mg/dl suggesting 
that periodontal disease is exacerbated by metabolic syndrome. (NCEP 2000). 
 Losche et al in 200059 showed that the plasmatic level of lipids in 
periodontitis patients were significantly higher than the healthy individuals. 
 Noack et al in 200075 studied 100 subjects and suggested that hyperlipidemia 
is a risk factor for periodontal disease, while impaired glucose tolerance is not. 
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 In 2002, Katz et al51 evaluated the periodontal health of over 10000 Israeli 
military service men and women and compared the results with their blood lipid 
levels and did not find a significant association between the presence of periodontal 
pockets and high levels of triglycerides.  
While some authors like Katz et al 200150, 200251 mentioned that there were 
significant correlations between periodontal status and cholesterol levels, whereas 
Cutler et al 199924, Morita et al 200471 , indicate that there were significant 
association between trigyceride level and periodontal disease. 
A study by Aki Izumi et al on 20091 showed that higher total cholesterol is 
associated with lower prevalence of periodontitis in non smoking elderly patients. 
After periodontal treatment, significant increase in serum HDL-C 
concentration, HDL2/HDL3 and HDL phospholipids content were observed. In this 
study, Pussinen et al 200477 stated that periodontitis decreases the antiatherogenic 
potency of HDL. 
 
PERIODONTITIS AND DIABETES: 
Williams and Mahan (1960100) reported a significant reduction in insulin 
requirements in 7 of 9 patients with diabetes and periodontal disease who underwent 
periodontal therapy. As such, diabetes may be adversely influenced by periodontal 
disease and conversely, periodontal disease may be more severe in the diabetic 
patient. This is important in that periodontal therapy may alter the patient’s insulin 
requirement, thus requiring an adjustment in the insulin dosage. Therefore, it is 
important to inform the patient’s physician prior to initiating periodontal therapy. 
Glavind et al. (196843) studied controlled diabetics aged 20 to 40 and 
compared them to a normal population. The investigators found no difference in the 
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populations up to the age of 30 years; however, patients older than 30 or patients who 
had been diagnosed with diabetes longer than 10 years had significantly more 
periodontal attachment loss. 
Cohen et al. (197020) compared diabetic and non-diabetic patients over a 2-
year period and consistently observed more gingival inflammation and attachment 
loss in the diabetic patients at each examination. Increased glucose has been found in 
the gingival crevicular fluid (GCF). This altered the environment and might allow the 
growth of different subgingival bacteria and/or alter PMN function (Kjellman et al., 
197054). Polymorphonuclear leukocytes (PMNs) functions, such as chemotaxis and 
phagocytosis, have been shown to be decreased in diabetic patients with periodontal 
disease (Manouchehr-Pour et al., 198163). 
Cianciola et al. (198219) demonstrated increased bone and attachment loss 
(periodontitis) in IDDM patients, compared to controls (siblings of the diabetics and 
non-related, nondiabetic patients) despite comparable plaque indices. 
In contrast to the above studies, Barnett et al. (19846) examined forty-five 10- 
to-18-year-old diabetic patients and found no correlation between the degree of 
diabetic control and the duration of diabetes compared to either the gingival index or 
the periodontal index. While this study conflicted with previous studies, it should be 
pointed out that none of the patients in this study exhibited any loss of interproximal 
bone, thus making comparison with previous studies difficult. In addition, these 
subjects were a rather homogeneous group from a private endocrinology practice and 
were probably very compliant. 
Novaes et al. (199176) compared the periodontal status of 30 Brazilian IDDM 
patients ages 5 to 18 with non-diabetic controls. They concluded that: 1) a statistically 
higher accumulation of plaque occurs among the diabetic patients (1.23 versus 0.81), 
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among female diabetics (1.34 versus 1.10), and among older patients (difference 
significant at the 5% level); 2) the gingival index was higher among diabetics than 
controls (0.52 versus 0.15), with no significant difference with respect to age and sex; 
3) probing depth did not differ significantly between diabetics and controls in relation 
to increasing age, but in relation to sex, diabetic females showed deeper pockets in the 
palatal region; and 4) alveolar bone loss was significantly greater in diabetics than in 
non-diabetics in the upper and lower anterior region.  
Seppala et al. (199388) evaluated the progression of periodontal disease in 
subjects aged 35 to 55 years with longstanding, insulin-dependent diabetes mellitus. 
They report that under similar plaque conditions, poorly-controlled diabetics have 
more gingivitis, more bleeding on probing, greater loss of attachment, and more bone 
loss than well-controlled subjects. 
Therefore considering the diversity of the few developed studies, as well as 
the different eating habits and studied populations, new researches to establish the real 
systemic changes caused by periodontitis are appropriate in order to explain the 
metabolic and physiologic changes responsible for changes in general health and in 
the increased susceptibility for certain systemic diseases. 
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MATERIALS AND METHOD 
SUBJECT SELECTION 
On getting approval from institutional ethical committee, from among the 
subjects who attended the Out patient clinic, Department of Periodontics, TamilNadu 
Government Dental College and Hospital, Chennai – 600 003, thirty individuals with 
Healthy Periodontium were taken as control group and thirty patients  diagnosed with 
Chronic Periodontitis were taken as the Study Group.  
INCLUSION CRITERIA 
Control group 
This included 30 individuals with the following features: 
• Bleeding on Probing  
• Absence of Clinical Attachment loss as determined by CAL (Clinical 
Attachment Level) measurements i.e. CAL=0. 
Study Group 
 The patients in the study were divided into mild, moderate and severe based on CAL.  
Mild   - 1-2mm of CAL  
Moderate  - 3-4mm of CAL 
Severe  - >5mm of CAL 
EXCLUSION CRITERIA           
• Diabetes Mellitus 
• Myocardial Infarction 
• Stroke 
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• Dental treatment during past 6 months 
• Smoking 
• Patients on statins / any drugs against hypercholesterolaemia. 
• Pregnancy/ Lactation 
• Liver dysfunction   
• Hypertension  
STUDY PROTOCOL 
1. Approval by the institutional ethical committee  
2. Medical History and Informed Consent 
3. Periodontal Examination using clinical parameters namely Probing Pocket 
Depth and Clinical Attachment Level. 
4. Collection of blood samples  
5. Enzymatic estimation of lipid profile and glucose levels 
 Following selection of subjects, written informed consent, which was 
approved by the Institute’s Ethical Committee, was obtained from all the subjects 
selected for the study after explaining the study procedure. Examination was preceded 
by a thorough medical and dental history of the subjects. Intra-oral examination was 
done using mouth mirror and William’s Periodontal Probe. Periodontal Evaluation 
was done by measuring the Probing Pocket Depth (PPD) and Clinical Attachment 
Level (CAL). 
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CLINICAL PARAMETERS (17, 45) 
PROBING POCKET DEPTH (PPD) 
Probing Pocket Depth was measured from the gingival margin to the base of 
the pocket using William’s Periodontal Probe. The probe was passed within the 
gingival sulcus along the circumference of the tooth.  
Three measurements were made on the buccal aspect and three on the lingual 
aspect of each tooth – total of six sites per tooth (Mesiobuccal, Midbuccal, 
Distobuccal, Mesiolingual, Midlingual, Distolingual). 
Probing depth per tooth             =   Sum of all scores per tooth  
             6 
Mean probing depth per person =    Sum of tooth score   
                       Total number of teeth examined  
 
 CLINICAL ATTACHMENT LEVEL (CAL) 
Clinical Attachment Level was measured from the Cemento – Enamel Junction 
(CEJ) to the base of the pocket using William’s Periodontal Probe.  
• When the gingival margin was located on the anatomic crown, the level of the 
attachment was determined by subtracting from the probing pocket depth, the 
distance from the gingival margin to the CEJ. If both were the same, the loss 
of attachment was calculated to be zero.  
• When the gingival margin coincided with the CEJ, the loss of attachment was 
calculated as equaling the probing pocket depth.  
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• When the gingival margin was located apical to the CEJ, the loss of 
attachment was greater than the probing pocket depth and therefore the 
distance between the CEJ and the gingival margin were added to the PPD. 
Three measurements were made on the buccal aspect and three on the lingual 
aspect of each tooth – total of six sites per tooth (Mesiobuccal, Midbuccal, 
Distobuccal, Mesiolingual, Midlingual, and Distolingual).  
CAL per tooth              =   Sum of all scores per tooth  
           6 
 
Mean CAL per person =    Sum of tooth score   
              Total number of teeth examined  
 
BLOOD SAMPLE COLLECTION 
Sterile disposable 2ml syringe, with 23 gauge disposable needle, were used to 
obtain the required blood samples. Venous blood samples were obtained after 12 
hours fasting, by venepuncture of cubital vein in the anticubital fossa. The blood was 
then transferred to previously sterile test tubes containing EDTA and transported to 
the clinical laboratory for processing. 
 
CHOLESTEROL (ENZYMATIC COLORIMETRIC TEST) 
PRINCIPLE 
Cholesterol and its esters are released from lipoproteins by detergents. 
Cholesterol esterases hydrolyses the esters, and H2O2 is formed in the subsequent 
enzymatic oxidation of cholesterol by cholesterol oxidase according to following 
reaction. 
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    Cholesterol 
Cholesterol esters + H2O2     --------------> Cholesterol and fatty acids. 
    Esterase 
 
 
       Cholesterol 
Cholesterol + O2   ------------> Cholesten-3-on + H2O2 
                               Oxidase 
 
     Peroxidase 
2H2O2 + Phenol + 4 aminoantipyrine -------------> quinoneimine dye + 4H2O 
 
REAGENT CONCENTRATION 
Reagent / R1 (Buffer) 
 
 Pipes buffer, PH 6.9  90mmol/litre 
 Phenol    26mmol/litre 
 
Reagent / R2 (Enzyme Reagent) 
 
 Cholesterol oxidase  200 U/I 
 Cholesterol esterase  300 U/I 
 Peroxidase   1250 U/I 
 4-Aminoanipyrine  0.4mmol/l 
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Reagent / R4 (standard) 
  Cholesterol   200 mg/dl (5.17 mmol/l) 
  
PREPARATION AND STABILITY 
Dissolve contents of enzyme reagent / R2 with corresponding volume of buffer 
/ R1. 
 
SAMPLES 
Serum, Plasma collected with sodium citrate. 
PROCEDURE 
Wavelength  :  546nm (500-550nm) 
Temperature  :  +25/ +30/+37O C 
Cuvette  :  1cm light pathway 
Zero adjustment :  Reagent blank one reagent blank per series only. 
 
   Blank  Standard Sample 
Standard  -  10µl  - 
Sample  -  -  10µl 
Working Reagent 1000µl  1000µl  1000µl 
Mix, measures after incubating at +37O C for 5mins. Within 60 minutes read 
absorbance of ample against reagent blank. 
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CALCULATION 
By standard 
  
Δ A sample 
______________   X   standard conc. = Cholesterol concentration 
Δ A sample      
   
Normal value  - < 200mg/dl 
HDL CHOLESTEROL 
PHOSPHOTUNGSTIC ACID METHOD – END POINT 
METHODOLOGY 
Burstein et al 
PRINCIPLE 
Chylomicrons, LDL, & VLDL (Low and Very low density lipoproteins) are 
precipitated from serum by phosphotungstate in the presence of divalent cations such 
as magnesium. The HDL cholesterol remains unaffected in the supernatant and is 
estimated using ERBA cholesterol reagent. 
 
Phosphotungstate 
Serum/Plasma  ------------------> HDL   + (LDL + VLDL) 
   Mg2+          (supernatant)      (Precipitate) 
 
REAGEANT COMPOSITION 
Reagent I: Precipitating Reagent 
Phosphotungstic Acid  : 2.4mmol/L 
 Magnesium Chloride  :  40mmol/L 
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Reagent II: HDL cholesterol standard 
HDL cholesterol standard :  25mg/dl 
Sample: 
 Unhemolysed serum or plasma 
PRECIPITATION 
Precipitation of LDL 
Pipette   Volumes 
 Sample  250µL 
 Precipitant Reagent 500 µL 
 Mix well and allow the reaction mixture to stand for 10 mins at room 
temperature, centrifuge at 400rpm for 10minutes to obtain a clear supernatant. Use the 
supernatant to determine the concentration of HDL cholesterol in the sample. 
 
ASSAY PROCEDURE 
Pipette into tubes marked  Blank  Standard Test 
Cholesterol working Reagent 100µl  1000µl  1000µl 
Distilled Water   50µl  -  - 
HDL standard   -  50µl  - 
Supernatant    -  -  50µl 
Mix well, incubate for 10min at 37ºC or 12min at 30ºC read the absorbance of 
standard and each sample at 510nm or 510/630nm for bichromatic analyzer against 
reagent blank. 
 
      Absorbance of sample 
HDL =     ----------------------------    X   Value of standard (mg/dl)   X   dilution factor 
      Absorbance of standard  
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         Absorbance of sample 
                 ----------------------------    X   25   X   3 
      Absorbance of standard  
 
 Absorbance of sample 
  ----------------------------    X 75 
 Absorbance of standard  
 
Normal value: 
 HDL > 40-50mg/dl  
TRIGLYCERIDES 
METHOD 
 Colorimetric Enzymatic test with turbidity cleanser. 
PRINCIPLE 
 
   LPL 
Triglycerides  ----->  Glycerol + fatty acids 
 
     GK   
Glycerol + ATP ----->  Glycerol – 3 phosphate + ADP 
 
    
GPO 
Glycerol-3 phosphate + O2 -----> Dihydroxy Acetone Phosphate + H2O2 
 
2H2O2 + Aminoantipyrine + 4 Chlorophenol ----> Dihydroxy + 4H2O2 
 
 
CONTENTS 
 R1 - Mono Reagent. 
R2 -  Standard 200mg/dl. 
 
SAMPLE  
Serum or Citrated Plasma 
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PROCEDURE 
Pipette into cuvettes 
 
   Blank  Sample/standard 
Mono Reagent 1000µl  1000µl 
Sample/standard -  10µl 
 
Mix, well incubate for 5 minutes at 37O C or for 10 minutes at room 
temperature. Read the absorbance ΔA of standard/sample against blank. 
 
CALCULATION 
     Δ A Sample 
Triglycerides (mg/dl) = -------------- X 200 
     Δ A Sample 
 
NORMAL VALUE: 
 Less than 150mg/dl. 
 
LDL CHOLESTEROL 
LDL Cholesterol is determined using Friedwald Formula 
LDL-C = Total Cholesterol – HDL-C + Triglycerides / 5. 
 
NORMAL VALUE 
 < 130 mg/dl 
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GLUCOSE 
PHOTOMETRIC DETERMINATION OF GLUCOSE 
PRINCIPLE 
    GOD 
Glucose + O2 + H2O2   --------> Gluconic acid + H2O2 
 
       Peroxidase 
2H2O + 4 Aminoantipyrine + Phenol ---------------> Quinoneimine + 4H2O2 
 
REAGENTS USED 
Reagent 1 
 
 Phosphate buffer PH 7.0 : 100mmol/l 
 Phenol    :  5mmol/l 
 4-aminoantipyrine  :   0.5mmol/l 
 Glucose oxidase  :  15KU/I 
 Peroxidase   :  1 KU/I 
 
Reagent 2: 
Glucose 
SAMPLE  
 Serum, Sodium citrated plasma 
 
PROCEDURE: 
 Reagent temperature  : +37O C 
 Wavelength   :  500nm. Hg 546nm 
 Light path   :  1cms 
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Measuring Temperature : +37O C  
 
   Sample Standard Blank 
Sample  10µl  -  - 
Standard  -  10µl  - 
Reagent  1000µl  1000µl  1000µl 
 
CALCULATION 
Glucose (mg/dl) = As / Astd X Conc. of Standard. 
 
NORMAL RANGE:   
90-110mg/dl 
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STATISTICAL ANALYSIS 
   
In a one-way ANOVA, the F statistic tests whether the treatment effects are all 
equal, i.e. that there are no differences among the means of the J groups. A significant 
F value indicates that there are differences in the means, but it does not tell you where 
those differences are, e.g. group 1’s mean might be different than group 2’s mean but 
not different from group 3’s mean.  
To isolate where the differences are, you could do a series of pairwise T-tests. 
The problem with this is that the significance levels can be misleading. For example, 
if you have 7 groups, there will be 21 pairwise comparisons of means; if using the .05 
level of significance, you would expect at least one statistically significant difference 
even if no differences exist.  
Therefore, various methods have been developed for doing multiple 
comparisons of group means. In SPSS, one way to accomplish this is via the use of 
the /POSTHOC parameter on the One-way command. We’ll present the SPSS output 
and then explain what the different parts mean. 
MEAN DIFFERENCE. 
 This column gives the difference in the means of the 2 groups 
STANDARD ERROR.  
In a One-way Anova, the standard error of the difference between the two 
means of groups i and j is  
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SIGNIFICANCE: 
This column gives you the significance of the difference under the multiple 
comparison method being used. To understand this, we need explain following 
method being used and what their rationale is. 
When the decision from the One-Way Analysis of Variance is to reject the null 
hypothesis, it means that at least one of the means isn't the same as the other means. 
What we need is a way to figure out where the differences lie, not just that there is a 
difference.  
This is where the Tukey tests come into play. They will help us analyze pairs of 
means to see if there is a difference much like the difference of two means covered 
earlier 
The formulas refer to mean i and mean j. The values of i and j vary, and the total 
number of tests will be equal to a combination of k objects, 2 at a time C(k,2), where 
k is the number of samples. 
TUKEY’S HSD POST-HOC TEST 
` A post-hoc test is needed after we complete an ANOVA in order to determine 
which groups differ from each other. Do not conduct a post-hoc test unless you found 
an effect (rejected the null) in the ANOVA problem. If you fail to reject the null, then 
there are no differences to find.. 
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For the Tukey’s post-hoc test we will first find the differences between the 
means of all of our groups. We will compare this difference score to a critical value to 
see if the difference is significant. The critical value in this case is the HSD (honestly 
significant difference) and it must be computed. It is the point when a mean difference 
becomes honestly significantly different. 
                           
Note that “q” is a table value, and n is the number of values we are dealing 
with in each group (not total n). The Mean Square value is from the ANOVA you 
already computed. To find “q” or the student zed range statistic, refer to your table on 
page A-32 of your text. On the table ‘k’ or the number of groups is found along the 
top, and degrees of freedom within is down the side. Cross index the row and column 
to find the value you need to put in the formula above. 
The test statistic is found by dividing the difference between the means by the 
square root of the ratio of the within group variation and the sample size 
                        
INDEPENDENT t TEST 
The independent t-test, as we have already mentioned is used when we wish to 
compare the statistical significance of a possible difference between the means of two 
groups on some independent variable and the two groups are independent of one 
another. 
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The formula for the independent t-test is 
,  
where 
is the mean for group 1, 
is the mean for group 2, 
is the sum of squares for group 1, 
is the sum of squares for group 2, 
n1 is the number of subjects in group 1, and 
n2 is the number of subjects in group 2. 
The sum of squares is a new way of looking at variance. It gives us an indication of 
how spread out the scores in a sample are. The t-value we are finding is the difference 
between the two means divided by their sum of squares and taking the degrees of 
freedom into consideration. 
 
and 
 
We can see that each sum of squares is the sum of the squared scores in the sample 
minus the sum of the scores quantity squared divided by the size of the sample (n). 
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So to calculate the independent-t value we need to know: 
1. The mean for sample or group 1  
2. The mean for sample or group 2  
3. The summation X and summation X squared for group 1  
4. The summation X and summation X squared for group 2  
5. The sample size for group 1 (n1)  
6. The sample size for group 2 (n2)  
We also need to know the degrees of freedom for the independent t-test which is: 
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Photograph 1 
Armamentarium 
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Photograph 2 
Control Group (Healthy) 
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Photograph 3 
Study Group (Chronic Periodontitis) 
 
 
 
 
 
Photograph 4 Williams’s periodontal probe used to measure 
probing pocket depth and CAL 
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Photograph 5 
Collection of blood sample  
 
 
 
 
 
Photograph 6 
Collected blood sample  
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Photograph 7 
Erba Chem 7 analyser used for estimating blood glucose and lipid 
levels 
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RESULTS 
Sixty subjects were included in the study. Among them thirty subjects with 
CAL = 0mm were taken as controls (healthy periodontium) and thirty subjects divided 
into mild(CAL=1-2mm), moderate(CAL=2-3mm) and severe(CAL ≥5mm) were 
taken as study group.The clinical parameter used for analysis and comparison 
between the two groups was clinical attachment level (CAL) which is a measure of 
loss of attachment. Blood parameters used are glucose and lipid profile levels. The 
difference between the groups in the blood parameters were taken into consideration 
for analyzing whether periodontitis is a risk factor for CVD.  
 
Table 1 and Table 2 show the values of Clinical Attachment Level (in mm) and 
levels of blood glucose, total cholesterol, HDL, triglycerides, LDL, (in mg/dl) in 
Study and control groups respectively  
Table 3 (Fig 1) shows the mean values and standard deviation of blood glucose and 
lipid levels in control and mild, moderate and severe periodontitis patients. 
Mean values of glucose in severe periodontitis patients (103) is greater than 
that of controls (75.60) but the P value is not statistically significant. All the values of 
lipid parameters except LDL showed high mean values in study group compared to 
control group but the P value is not significant except in TGL. In all the parameters 
except LDL and HDL the mean values of severe periodontitis group is greater than 
that of control group as well as mild, moderate and severe periodontitis group. 
In TGL, mean values of control is 86.60 where as in severe periodontitis it is 
230.70. This is statistically significant with P value of 0.000. 
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Table 4 shows the proportion of abnormality in study group. This table shows 
that in glucose, the number of patients beyond the cut off value is 7 and among these 
7, 4 of them belong to severe periodontitis group (57.14%). 
In total cholesterol, the total number of patients beyond the cut off value is 6, 
among these 3 of them belong to severe periodontitis group. (50%). 
In TGL, 11 patients out of 30 patients were above the cut off value and of 
these 10 patients belong to the severe periodontitis group (90.9%). 
In HDL, the number of patients below the cut off value is 4, 2 (50%) belong to 
moderate periodontitis group and one of them belong to severe and another one 
belongs to mild periodontitis patients. 
In LDL, the number of patient above the cut off value is 4 and out of 4, 3  
(75%) of them belong to mild periodontitis group. 
In all these parameters, except HDL and LDL, the maximum number of 
patients belongs to severe periodontitis group. 
Table 5 shows the proportion of abnormality in control group. In this table, it 
shows the total number of patients beyond the pathological value is 3 out of 30 
individuals. In the lipid parameter, all patients exhibited below the cut off value 
except HDL in which 8 of them were with pathological cut off value. 
Table 6 shows the mean standard deviation and standard error mean values 
between study and control group. 
In this table, independent t test was used and the values are matched between 
control and study group. Mild, moderate, and severe periodontitis patients in the study 
group were clumped into single group and analyses were made. 
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According to this test, mean values of all the blood parameters in the study 
group was greater than that of control except LDL in which the mean values of study 
group is 94.420 whereas in control group it is 96.327. 
Table 7 shows the P values of the blood parameters using independent t test between 
control and study group. 
In this, P value of total cholesterol is 0.002 and TGL is 0.000 which is 
statistically significant. Other values are not statistically significant. 
Figure 2 shows the comparison of CAL in control and mild, moderate and severe 
periodontitis patients 
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1 42/F 60 164 54 104 89.2 1.2 44/M 70 190 48 140 114 3.6 37/M <60 146 43 238 55.4 5.3 
2 42/M 73 126 42 102 63.6 1.2 52/M 56 153 48 142 76.6 3.8 70/F 109 208 42 182 129.6 5.08 
3 35/M <60 152 47 106 83.8 1.18 33/F 55 153 38 148 85.4 3.5 37/M 91 158 40 162 85.6 .5.02 
4 40/F <60 135 38 102 76.6 1.4 37/F 60 140 43 156 65.8 3.7 60/M 126 223 43 179 144.2 5,12 
5 37/M 203 164 48 110 92 1.4 40/F 60 182 48 126 108.2 3.2 35/F 176 197 59 192 99.6 5.1 
6 35/F 60 198 45 110 131 1.5 49/M <60 192 51 118 117.4 3.1 45/F 74 213 45 291 109.8 5.2 
7 45/F 60 125 35 120 66 1.8 36/M 90 141 39 122 77.6 3.2 46/F 61 186 42 224 99.2 5.2 
8 33/F 60 200 41 105 138 1.3 40/F 126 207 45 120 138 3.2 35/F 99 148 42 239 58.2 5.2 
9 40/M 60 227 43 108 162.4 1.2 37/M 75 147 47 128 74.4 3.3 50/F 76 162 40 276 66.8 5.2 
10 63/M 112 178 `43 115 112 1.7 35/F 62 142 47 125 70 3.3 39/F 168 146 39 324 42.2 5.4 
Table1 master chart study group 
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Table 2 Master chart (control group) 
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1 50/F <60 152 49 97 83.6 0 
2 42/M 70 198 45 70 1284 0 
3 36/F 115 150 45 105 84 0 
4 40/M 70 141 47 104 73.2 0 
5 60/F 89 168 42 106 104.8 0 
6 35/F 70 186 43 72 128.6 0 
7 42/M 84 162 45 98 97.4 0 
8 45/F 60 148 40 98 92.4 0 
9 40/M 60 174 40 96 114.8 0 
10 40/F <60 168 45 97 104 0 
11 60/M 58 163 40 93 106.4 0 
12 35/M 67 148 52 98 76.4 0 
13 45/F 60 130 40 77 74.6 0 
14 35/F 68 141 40 82 86.6 0 
15 40/M <60 125 40 61 78.8 0 
16 42/F <60 181 40 74 129.2 0 
17 40/F 60 190 41 62 186.6 0 
18 35/M 216 142 40 80 87 0 
19 35/M 68 147 48 62 86.6 0 
20 37/M <60 152 40 57 104.6 0 
21 49/M 157 149 40 84 93.2 0 
22 36/M 79 146 42 98 84.4 0 
23 41/M 84 153 42 90 93 0 
24 42/F 70 149 42 70 93 0 
25 36/F 70 154 42 87 94.6 0 
26 40/F 60 152 49 97 83.6 0 
27 42/F 60 132 42 96 70.8 0 
28 37/M 70 140 45 107 73.6 0 
29 52/M 83 152 47 82 88.6 0 
30 47/F 70 162 40 98 104.4 0 
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Table 3: Blood lipid and glucose levels (mg/dl) mean and standard deviation in 
controls and mild, moderate and severe periodontitis patients(Study group) 
 
 
 
 
Table 4: Frequency of pathological values of plasma lipids and blood glucose 
levels in periodontitis patients. (Study group) 
 
Cut off (mg/dl) Study Under Beyond 
Glucose >100 23 7 
Total 
cholesterol >200 24 6 
TGL >150 19 11 
HDL <40 4 26 
LDL >130 26 4 
 
 
 
 
Table 5: Frequency of pathological values of plasma lipids and blood glucose 
levels in controls  
 
Cut off (mg/dl) Controls Under Beyond 
Glucose >100 27 3 
Total 
cholesterol >200 30 0 
TGL >150 30 0 
HDL <40 0 30 
LDL >130 30 0 
 
 
 
 
Blood 
parameters 
(mg/dl) 
Control Study p-
value Mild Moderate Severe Mean  SD Mean  SD Mean SD Mean SD 
Glucose  75.60 34.106 78.80 47.126 70.40 22.717 103.00 42.716 .178 
Total 
cholesterol 156.00 19.946 166.90 34.129 164.70 25.272 178.70 30.137 .106 
TGL 86.60 14.956 108.20 5.789 132.50 13.058 230.70 53.564 .000 
HDL 42.37 4.319 43.67 5.657 45.40 4.195 43.50 5.720 .377 
LDL 96.327 20.9494 101.460 33.154 92.74 24.654 89.060 33.527 .737
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Table 6: Mean and Standard Deviation of the Blood Glucose and Lipid levels in 
control and study group 
 
 
 
 
 
 
 
Table 7: p-values calculated used independent t test between control and study 
group 
Blood parameters p-value 
Glucose .129 
Total cholesterol .002 
TGL .000 
HDL .493 
LDL .016 
 
 
 
 
 
 
 
 
 
Group Statistics
30 84.07 40.165 7.333
30 75.60 34.106 6.227
30 170.10 29.676 5.418
30 156.00 19.946 3.642
29 44.21 5.109 .949
30 42.37 4.319 .789
30 157.13 62.088 11.336
30 86.60 14.956 2.731
30 94.420 30.1097 5.4973
30 96.327 20.9494 3.8248
30 3.32 1.588 .290
30 .00 .000 .000
Group
Study Group
Control Group
Study Group
Control Group
Study Group
Control Group
Study Group
Control Group
Study Group
Control Group
Study Group
Control Group
Glucose(mg/dl)
Total cholesterol 
HDL 
TGL 
LDL 
CAL 
N
Mean Std.  
Deviation 
Std. Error
Mean
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DISCUSSION 
   
The periodontium has been described as a potential reservoir of endotoxin, 
cytokines and lipid mediators in the body. The administration of low dosages of 
endotoxin in rodents rapidly induces changes in lipid metabolism resulting in hyper 
triglyceridemia.  Infection with P.gingivalis or other gram negative periodontal 
pathogens could trigger the systemic release of IL-1 beta and TNF-alpha altering fat 
metabolism resulting in chronic hyper triglyceridemia. When periodontitis was 
induced in rats by administration P.gingivalis serum TGL increased (Memon et al 
199368).  
In the present study both sexes were included similar to other studies (Cutler 
199923 Joseph Katz 200251, Katz 200150, Loesche 200059 
Cutler et al23 in his study selected sample with age group of 25 to 60 years 
but in the present study the age group selected is 35 to 70 years for both group. 
The other confounding factors related to elevated cholesterol level like 
smoking, hypertension, lever disease were eliminated in the present study similar to 
earlier studies. (Loesche 200059). 
According to Katz et al 200251 smoking status is positively correlated with 
TC, LDL and TGL and negatively associated with HDL cholesterol. Vasoconstriction 
of gingival blood vessels caused by smoking promoted invasion of periodontal 
disease by micro organism (Loesche 199861), Hence smokers was excluded from the 
study. 
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By following the earlier studies (Christopher Cutler, 199923) patients with 
normal blood pressure were taken in the present study.  
A hyper responsive monocytic state of chronic periodontitis results in further 
elevation of serum pro inflammatory cytokines and lipids hence patients with chronic 
periodontitis was taken in the present study (Salvi et al 199886) 
In this study, CPITN probe was not used because it has been claimed that 
CPITN findings over estimated both prevalence and severity of periodontal 
attachment loss among young age groups, but underestimated these parameters among 
older subjects (Baeleum et al 19955),instead Williams periodontal probe was used in 
this study. 
 Although there are several studies reporting the association between 
periodontitis and systemic lipid levels, the results remain controversial. In some 
studies (Katz 2001, 200250, 51), TC and periodontitis exhibited significant relationship 
whereas in other studies (Cutler et al 199923, Morita et al 200471), TGL showed 
significant relationship to periodontitis. This discrepancy may arise from the 
methodological difficulties associated with the complexity of lipid metabolism and 
variety of metabolic lipid parameter. 
In this study, the patients in the study group were categorized into mild, 
moderate & severe based on the CAL and compared with the controls for the blood 
lipids and glucose levels to investigate whether the lipid profile and glucose 
parameters alters with increasing severity of the study. Within the limits of our 
knowledge, no study has been done before correlating the severity of the disease with 
the lipid profile and glucose levels. 
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According to our results, plasma level of TGL was significantly higher in 
mild, moderate, and severe periodontitis group when compared with age & sex 
matched controls. (P>0.000). 
This result was found to be consistent with Matilla et al66 who found 
significant association between TGL and dental infection. 
When mild, moderate and severe periodontitis were taken as one group & 
compared with control group, TC was statistically significant. This result was found 
to be concurrent with Cutler et al23 who found that presence of periodontitis was 
significantly associated with increase in TC level but in this study TGL was not 
significantly associated with periodontitis. 
In our study, the frequency of pathological TGL and TC levels were more 
prevalent in patients with periodontitis than in control in agreement with Loesche et 
al59.However in this study, we did not find significant differences between the groups 
for LDL and HDL cholesterol. 
Katz et al51 suggested that patients with hypercholesterolemia have more 
severe periodontal disease. However in the same study, no association was found with 
regard to TGL. Saito et al84 and Wakai et al97 also did not mention a significant 
association between periodontal status and TGL level. Morita et al71 indicated that 
elevated TGL level might be potential indicator for the presence of the periodontal 
disease. Cutler et al23 reported that elevated TGL levels are able to modulate IL-1beta 
production by PMN that are stimulated by P.gingivalis LPS. 
Anna Cristina et al 20054, found no significant relationship between 
periodontal disease, regardless of its intensity and blood lipid levels in the studied 
population. 
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Our findings indicate strong association between plasma TGL levels and 
periodontal disease. However some methodological limitation should be kept in mind 
when interpreting our result. First, because this study had a case control design, it is 
difficult to make causal inferences based on its findings. Second, the sample size is 
small to give a consistent decision. Thirdly, no intervention studies have been done. 
Though diabetes is an exclusion criteria in our study, fasting glucose levels 
were measured. The level of glucose in severe periodontitis patients was not 
statistically significant when compared to controls, but the means of glucose levels in 
severe periodontitis was higher than that of controls. 
The results of this study regarding blood glucose levels were in accordance 
with Loesche et al 200059. This indicates that systemically healthy patients with 
severe periodontitis demonstrated significantly higher blood glucose levels than 
patients without periodontitis. This observation may indicate that patients with 
periodontitis have impaired glycemic control and are in a “prediabetic state.” 
Thus infection-induced insulin resistance syndromes, if longstanding or 
chronic, are considered to be precursors to active diabetes due to the pancreatic β-cell 
destruction that results from sustained elevations of IL-1beta/TNF-alpha. In fact, 
some investigators suggest that a “proinflammatory imbalance” created by IL-
1beta/TNF-alpha is one of the most critical determinants of β-cell loss in diabetic 
patients (Netea et al 199773). 
It has been suggested that proinflammatory cytokines such as IL-1beta and 
TNF-alpha, produced as a systemic response to periodontal infection are responsible 
for insulin resistance and subsequent poor glycemic control in periodontitis patients. 
In order to determine whether periodontitis induces insulin resistance and a 
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prediabetic condition, future studies will need to evaluate prediabetes in a very precise 
and consistent manner. 
The two way relationship between diabetes mellitus and periodontal disease 
has been studied intensively in the past and has been subjected to large controversies. 
Very few studies however have investigated the role of glucose level in periodontitis 
patient & vice versa in non- diabetic patients. (Yousuf Khader 200896). 
A relationship between infection and lipid and glucose levels has been widely 
documented in past decades. Chronic infectious diseases are now thought to have an 
impact on plasma lipid (Gallin et al 196939). This dyslipidemia is thought to be a part 
of host response aimed at decreasing the toxicity of harmful microbiologic agent. 
This study gives another evidence for an association between severe 
periodontitis and alteration of lipid levels, which may be mediated by constant 
activation of inflammatory process determined by the presence of periodontal 
pathogens in periodontal pockets. (D’ Auito et al 200525). 
Bacteria such as P.gingivalis, one of the most common pathogens present in 
severe periodontitis are capable of stimulating a continuous release of pro 
inflammatory cytokines such as IL-1 IL-6, TNF alpha. These cytokines are believed 
to have direct or indirect effects resulting in enhanced elimination of TGL and 
increased lipolysis.(Feingold & Grunfeld 198732). 
The physical and chemical properties of cell membranes are largely 
determined by the nature of the fatty acids such as gamma linoleic acid within the 
phopholipid bilayer. Thus alteration of the lipids in the blood stream or tissues can 
have effect on molecules signaling via receptors. Lipids may interact directly with 
myeloid cells altering gene expression for pro inflammatory cytokines and essential 
growth factors. It is possible that abnormalities in macrophage function, caused by 
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elevations in serum lipids, alter the cytokine secretion necessary for normal wound 
healing to occur. Thus it is conceivable that periodontitis would be potential risk 
factor for CAD through long term alteration in fatty acid metabolism and potentiation 
of pro inflammatory cytokine production. 
According to American Journal of Cardiology & Journal of 
Periodontology, 2009, patients with periodontitis meeting criteria for metabolic 
syndrome should be identified and all the risk factors for atherosclerotic CVD should 
be treated, beginning with lifestyle changes aimed at weight reduction. 
Within the limits of case control design, this study supports the association 
between periodontitis and dyslipidemia which may predispose to more serious 
systemic complication. 
Finally, although longitudinal evaluation with a larger population may be an 
important step in revealing the causal relationship between periodontal disease and 
impaired lipid metabolism, our study may shed light on the clarification of this 
association in the future. 
 
 
 
 
 
 
 
 
 57
SUMMARY AND CONCLUSION 
 
Levels of blood glucose and lipid levels were determined in individuals of 
control group with CAL = 0 mm (healthy periodontium, n = 30) and in patients of 
study group with CAL ≥ 1-2mm (mild), CAL >3-4mm (Moderate), 
CAL>5mm(Severe)(Chronic Periodontitis, n = 30) by analyzing their blood samples 
from cubital vein in anticubital fossa. The blood was then transferred to previously 
autoclaved test tubes containing EDTA and transported to the clinical laboratory for 
processing. The data collected was statistically analyzed. 
According to the present study,  
• There is a statistically significant increase in the levels of TGL in the patients 
with Chronic Periodontitis when compared with those not affected by 
Periodontitis. 
• When mild, moderate and severe periodontitis were taken as one group and 
compared with control group, TC was stastiscally significant. 
• There is no significant difference in the levels of LDL-C, HDL-C and glucose 
between the patients of two groups. 
• As the severity of the disease increases, alteration in the blood parameters also 
increases.  
• Although the levels of blood glucose are elevated in patients with severe 
Chronic Periodontitis, this increase is not stastiscally significant. This may be 
due to the smaller sample size. 
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It is likely that severity and poor control of periodontal disease might affect the 
level of lipids and glucose in blood which may increase the risk for CVD. Therefore, 
when periodontitis is newly diagnosed in patients with atherosclerotic CVD, 
periodontists and physicians managing patients with CVD should closely collaborate 
to optimize CVD risk reduction and periodontal care in accordance with American 
Journal of Cardiology and Journal of Periodontology joint recommendation. 
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APPENDIX . Proforma and Informed Consent 
PROFORMA 
Blood Glucose levels and Dyslipidemia in Chronic Periodontitis Patients: 
Case Control study 
Date:                                                 Dental O.P. No:                                         Code 
No.:        
Name :                                             Age/Sex :                   
 
Tel. no. :               Mobile no. :    
 
Occupation :                  Income : 
 
Chief Complaints:    
 
Pain / shaky teeth / Bleeding gums / Swollen Gums / Receding Gums /Increase in 
Spacing between teeth / Pus Discharge / Stains/others 
Duration: 
Medical History: 
1. Diabetes mellitus 
2. Pregnancy / Lactation 
3. Cardiac diseases 
4. Stroke 
5. Any drugs against hypercholesterolemia 
6. Liver dysfunction 
7. Hypertension  
Dental History 
        Periodontal treatment within past 6 months 
Habits 
 Smoking 
 
 
 
  
 
Address :                                         
 72
Control Group            Study Group             
Code No: 
Clinical Examination 
     
PROBING DEPTH (PD) AND CLINICAL ATTACHMENT LEVEL 
(CAL) (in mm) 
Maxillary: 
Palatal 
 
CAL                 
PPD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PPD                 
CAL                 
Buccal 
Mandibular: 
Lingual 
CAL                 
PPD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PPD                 
CAL                 
Buccal 
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                                                                                      Code No:       
 
Blood Sample Details: 
 
Date: 
  
BLOOD PARAMETERS 
 
   GLUCOSE- 
LDL- 
HDL- 
TRIGLYCERIDES- 
TOTAL CHOLESTROL- 
 
 
INFERENCE 
 
 
 
 
 
 
 
 
 
 
Signature of PG student 
 
 
 
 
 
Date: 
Time:                                                                
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Informed Consent Form – English 
 
Study Title 
 
Blood glucose levels and Dyslipidemia in Chronic Periodontitis Patients; A Case 
control study  
Name:                                                                                         O.P. No: 
 
Address:                                                                                     Code No.: 
 
                                                                                                    Age / Sex: 
 
 
I,                                                                   Age                                                        yrs, 
exercising my free power of choice, hereby give my consent to be included as a 
participant in the study ‘Blood glucose levels and Dyslipidemia in Chronic 
Periodontitis Patients; A Case control study”. 
 
I agree to the following: 
 
• I have been informed to my satisfaction about the purpose of the study 
and study procedures including investigations to monitor and 
safeguard my body function. 
• I understand that the lab investigations will require the procurement of 
my blood in required amount. 
• I agree to cooperate fully and to inform my doctor immediately if I 
suffer any unusual symptom. 
• I have informed the doctor about all medications I have taken in the 
recent past and those I am currently taking.  
• I hereby give permission to use my medical records for research 
purpose. I am told that the investigating doctor and Institution will 
keep my identity confidential. 
 
 
 
Name of Patient                            Signature / Thumb impression                              
Date 
 
 
 
Name of Investigator                               Signature                              
Date 
Muha;r;rp xg;Gjy; gbtk; 
Muha;r;rp jiyg;G: 
ehs;gl;l  gy;iyr; Rw;wpa  jpRtpy;; Vw;gL;k; mow;rp  cs;s  Nehahspfspd;  
uj;jj;jpy; cs;s  rh;f;fiu  kw;Wk;  nfhOg;gpd; khw;wj;jpd; msT gw;wpa  Xh; 
Muha;r;rp. 
ngah; : ……………………………………….GwNehahspapd; vz;: ……………… 
Kftup : ……………………………Muha;r;rp Nrh;f;if     vz;: ………………. 
 ………………………………………..  taJ : 
        ………………………………………. ghypdk; Mz;       ng    
z; 
 ehs; …………………………..taJ ………………. vd;Dila  
RaepidTld; kw;Wk; KO Rje;jpuj;Jld;>  ,e;j kUj;Jt Muha;r;rp  vd;id 
nfhs;s rk;kjpf;fpNwd;. 
vdf;F  tpsf;fg;gl;l tp\aq;fSf;F ehd; vdJ rk;kjj;ijj; jUfpNwd;.  
¾ ,e;j Muha;r;rpapd; Nehf;fk;> kUj;Jt Kiwfs; ghpNrhjid  Kiwfs;   
vdf;F jpUg;jp jUk; tifapy;  tpsf;fg;gl;ld. 
¾ gupNrhjid   nra;tjw;fhf vd;  clk;gpypUe;J ,uj;jk; vLf;fg;gl 
Ntz;bAs;sjhf mwpfpNwd;. 
¾ ehd; vLj;JtUfpd;w kw;Wk; Kd; cl;nfhz;l kUe;Jfs; gw;wpa 
tptuq;fis Muha;r;rpahsh;fsplk; mwptpf;f  rk;kjk;. 
¾ vd; cly; eyk; ghjpf;fg;gl;lhNyh my;yJ vjph;ghuhj>  tof;fj;jpw;F 
khwhd  Neha;f;Fwp njd;gl;lhNyh  clNd  mij  kUj;Jtuplk; 
njuptpg;Ngd; vd cWjpaspf;fpNPwd;.   
¾ vdf;Fk;  kw;Wk; kUe;J Muha;r;rpahsUf;Fk; ,e;j Muha;r;rpapypUe;J   
ve;j xU  epiyapYk;  tpyFtNjh  my;yJ tpyf;Ftjw;Nfh KO 
cupik  ,Ug;gjhf  mwpfpNwd;.  
¾ vd;Dila  kUj;Jtf; Fwpg;NgLfis   ,e;j Muha;r;rpapy;  
gad;gLj;jpf; nfhs;s  rk;kjpf;fpNwd;.    Muha;r;rp ikaKk;>  
Muha;r;rpahsUk;  vd;Dila ngah;  kw;Wk; rpy  tptuq;fis  
,ufrpakhf itg;gjhf    mwpfpNwd;.   
 
 
---------------------------------------------------- --------------------------------     ------------- 
Nehahspapd; ngah;:    ifnaOj;J     Njjp:  
 
---------------------------------------------------- --------------------------------     ------------- 
Muha;r;rpahsupd;; ngah;:          
ifnaOj;J     Njjp:  
